Abliva AB Performance
| NEVPFDelisted Stock | USD 0.03 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Abliva AB are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Abliva AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Abliva AB is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 61.6 M | |
| Total Cashflows From Investing Activities | -1.1 M |
Abliva |
Abliva AB Relative Risk vs. Return Landscape
If you would invest 2.80 in Abliva AB on October 30, 2025 and sell it today you would earn a total of 0.00 from holding Abliva AB or generate 0.0% return on investment over 90 days. Abliva AB is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Abliva, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Abliva AB Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Abliva AB for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Abliva AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Abliva AB is not yet fully synchronised with the market data | |
| Abliva AB has some characteristics of a very speculative penny stock | |
| Abliva AB has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 151 K. Net Loss for the year was (123.49 M) with loss before overhead, payroll, taxes, and interest of (103.54 M). | |
| Abliva AB has accumulated about 4.32 M in cash with (114.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Abliva AB Fundamentals Growth
Abliva Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Abliva AB, and Abliva AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abliva Pink Sheet performance.
| Return On Equity | -0.8 | |||
| Return On Asset | -0.41 | |||
| Current Valuation | 10.01 M | |||
| Shares Outstanding | 1.06 B | |||
| Price To Earning | (2.49) X | |||
| Price To Book | 0.60 X | |||
| Price To Sales | 765.58 X | |||
| Revenue | 151 K | |||
| EBITDA | (120.72 M) | |||
| Cash And Equivalents | 4.32 M | |||
| Cash Per Share | 0.06 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (114.08 M) | |||
| Earnings Per Share | (0.11) X | |||
| Total Asset | 58.92 M | |||
| Retained Earnings | (29.41 M) | |||
| Current Asset | 13.44 M | |||
| Current Liabilities | 1.24 M | |||
About Abliva AB Performance
By analyzing Abliva AB's fundamental ratios, stakeholders can gain valuable insights into Abliva AB's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Abliva AB has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Abliva AB has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Abliva AB develops medicines for the treatment of primary mitochondrial diseases. Abliva AB was incorporated in 2000 and is headquartered in Lund, Sweden. ABLIVA AB is traded on OTC Exchange in the United States.Things to note about Abliva AB performance evaluation
Checking the ongoing alerts about Abliva AB for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Abliva AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Abliva AB is not yet fully synchronised with the market data | |
| Abliva AB has some characteristics of a very speculative penny stock | |
| Abliva AB has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 151 K. Net Loss for the year was (123.49 M) with loss before overhead, payroll, taxes, and interest of (103.54 M). | |
| Abliva AB has accumulated about 4.32 M in cash with (114.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Abliva AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abliva AB's stock is overvalued or undervalued compared to its peers.
- Examining Abliva AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abliva AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abliva AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abliva AB's pink sheet. These opinions can provide insight into Abliva AB's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Abliva Pink Sheet
If you are still planning to invest in Abliva AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Abliva AB's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |